Motzer RJ - Search Results

1

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ; CheckMate 9ER Investigators. Choueiri TK, et al. Among authors: motzer rj. N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982. N Engl J Med. 2021. PMID: 33657295 Free PMC article. Clinical Trial.

2

Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression.

Motzer RJ, Nanus DM, O'Moore P, Scher HI, Bajorin DF, Reuter V, Tong WP, Iversen J, Louison C, Albino AP, et al. Motzer RJ, et al. Cancer Res. 1992 Oct 15;52(20):5775-9. Cancer Res. 1992. PMID: 1394202 Clinical Trial.

3

A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.

Ilson DH, Motzer RJ, Kradin RL, Vogelzang NJ, Bajorin DF, Scher HI, Nanus D, O'Moore P, Marathias K, Bosl GJ. Ilson DH, et al. Among authors: motzer rj. J Clin Oncol. 1992 Jul;10(7):1124-30. doi: 10.1200/JCO.1992.10.7.1124. J Clin Oncol. 1992. PMID: 1607918 Clinical Trial.

4

Phase II trial of Didemnin B in patients with advanced renal cell carcinoma.

Motzer R, Scher H, Bajorin D, Sternberg C, Bosl GJ. Motzer R, et al. Invest New Drugs. 1990 Nov;8(4):391-2. doi: 10.1007/BF00198598. Invest New Drugs. 1990. PMID: 2084073 Clinical Trial.

5

Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma.

Law TM, Mencel P, Motzer RJ. Law TM, et al. Among authors: motzer rj. Invest New Drugs. 1994;12(4):323-5. doi: 10.1007/BF00873048. Invest New Drugs. 1994. PMID: 7775134 Clinical Trial.

6

Phase II trial of topotecan in patients with advanced renal cell carcinoma.

Law TM, Ilson DH, Motzer RJ. Law TM, et al. Among authors: motzer rj. Invest New Drugs. 1994;12(2):143-5. doi: 10.1007/BF00874445. Invest New Drugs. 1994. PMID: 7860232 Clinical Trial.

7

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.

Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE. Minasian LM, et al. Among authors: motzer rj. J Clin Oncol. 1993 Jul;11(7):1368-75. doi: 10.1200/JCO.1993.11.7.1368. J Clin Oncol. 1993. PMID: 8315435 Clinical Trial.

8

Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.

Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ, Scher HI, Geller NL, Fair WR, Herr H, Sogani P, et al. Bajorin DF, et al. Among authors: motzer rj. J Clin Oncol. 1993 Apr;11(4):598-606. doi: 10.1200/JCO.1993.11.4.598. J Clin Oncol. 1993. PMID: 8386751 Clinical Trial.

9

Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.

Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O'Connell M, Khan A, Vlamis V, Vogelzang NJ, Bajorin DF. Law TM, et al. Among authors: motzer rj. Cancer. 1995 Sep 1;76(5):824-32. doi: 10.1002/1097-0142(19950901)76:5<824::aid-cncr2820760517>3.0.co;2-n. Cancer. 1995. PMID: 8625186 Clinical Trial.

10

Renal-cell carcinoma.

Motzer RJ, Bander NH, Nanus DM. Motzer RJ, et al. N Engl J Med. 1996 Sep 19;335(12):865-75. doi: 10.1056/NEJM199609193351207. N Engl J Med. 1996. PMID: 8778606 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

606 results

Search Page